Drugs / APO-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04277598 | Oct 2020 → Dec 2023 | ulcer of lower limbs | Aposcience AG | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-08-31 | Aposcience AG | Results Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study aposcience.at ↗
Aposcience AG received the Recommendations of the Data Safety Monitoring Board (DSMB). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-08-31 | Aposcience AG | Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study aposcience.at ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APO-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04277598 ↗ |
| Modality | Protein / enzyme biologic | “the biologic investigational medicinal product (IMP) APO-2” NCT04277598 ↗ |
| Route | Topical | “APO-2: dose adjusted gel for topical administration.” NCT04277598 ↗ |